Literature DB >> 8230468

Comparing regions of the Epstein-Barr virus ZEBRA protein which function as transcriptional activating sequences in Saccharomyces cerevisiae and in B cells.

G Miller1, H Himmelfarb, L Heston, J Countryman, L Gradoville, R Baumann, T Chi, M Carey.   

Abstract

The ZEBRA protein activates expression of Epstein-Barr virus early-lytic-cycle genes in human B lymphocytes. Here it is shown that ZEBRA also behaves as a sequence-specific transcriptional activator in Saccharomyces cerevisiae. Deletional mutagenesis defined three regions of ZEBRA that participate in activation in S. cerevisiae. These regions are designated YI (amino acids [aa] 1 to 25), YII (aa 51 to 102), and YIII (aa 228 to 245). Two of the three regions of the native ZEBRA protein act together to mediate activation when assayed on ZEBRA binding sites. However, when fused to the DNA binding domain of GAL4 and assayed on GAL4 binding sites, regions YII and YIII were each sufficient to confer activation in S. cerevisiae. Regions of ZEBRA which affected activation in S. cerevisiae were also required in human B lymphocytes. The amino-terminal region of ZEBRA (aa 1 to 98) was required for activation both in S. cerevisiae and in human B cells; deletion of the carboxy-terminal 18 aa also significantly reduced activation in both cell types. Thus, the behavior of ZEBRA in human B cells and S. cerevisiae suggests that the protein contains universal activation motifs that interact with conserved components of the transcription machinery. However, certain deletion mutants of ZEBRA containing mutations in the N-terminal region exhibited discordant behaviors in S. cerevisiae and in B cells. For example, deletion of ZEBRA aa 26 to 51 impaired activation to a great extent in B cells but had little or no effect in S. cerevisiae. The discordant mutants may reflect interactions with a variable domain of a conserved component or unique interactions with specialized components of the basal transcription apparatus in different cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230468      PMCID: PMC238213     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  How eukaryotic transcriptional activators work.

Authors:  M Ptashne
Journal:  Nature       Date:  1988-10-20       Impact factor: 49.962

2.  Transfer and expression of plasmids containing human cytomegalovirus immediate-early gene 1 promoter-enhancer sequences in eukaryotic and prokaryotic cells.

Authors:  M G Davis; E S Huang
Journal:  Biotechnol Appl Biochem       Date:  1988-02       Impact factor: 2.431

3.  Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression.

Authors:  S J Triezenberg; R C Kingsbury; S L McKnight
Journal:  Genes Dev       Date:  1988-06       Impact factor: 11.361

4.  Deletion analysis of GAL4 defines two transcriptional activating segments.

Authors:  J Ma; M Ptashne
Journal:  Cell       Date:  1987-03-13       Impact factor: 41.582

5.  Mammalian glucocorticoid receptor derivatives enhance transcription in yeast.

Authors:  M Schena; K R Yamamoto
Journal:  Science       Date:  1988-08-19       Impact factor: 47.728

6.  Functional analysis of the papilloma virus E2 trans-activator in Saccharomyces cerevisiae.

Authors:  P F Lambert; N Dostatni; A A McBride; M Yaniv; P M Howley; B Arcangioli
Journal:  Genes Dev       Date:  1989-01       Impact factor: 11.361

7.  Sequences that regulate the divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae.

Authors:  M Johnston; R W Davis
Journal:  Mol Cell Biol       Date:  1984-08       Impact factor: 4.272

8.  Transformation of intact yeast cells treated with alkali cations.

Authors:  H Ito; Y Fukuda; K Murata; A Kimura
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

9.  Activation of yeast RNA polymerase II transcription by a thymidine-rich upstream element in vitro.

Authors:  N F Lue; A R Buchman; R D Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

10.  Use of lacZ fusions to delimit regulatory elements of the inducible divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae.

Authors:  R R Yocum; S Hanley; R West; M Ptashne
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

View more
  6 in total

1.  Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.

Authors:  Lee Heston; Ayman El-Guindy; Jill Countryman; Charles Dela Cruz; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras.

Authors:  J L Kolman; N Taylor; L Gradoville; J Countryman; G Miller
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.

Authors:  H M Cheng; Y T Foong; A J AbuSamah; J Dillner; C K Sam; U Prasad
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

4.  Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency.

Authors:  A L Francis; L Gradoville; G Miller
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Activation of the Epstein-Barr virus BMRF1 and BZLF1 promoters by ZEBRA in Saccharomyces cerevisiae.

Authors:  J K Countryman; L Heston; L Gradoville; H Himmelfarb; S Serdy; G Miller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 6.  Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion.

Authors:  Gaëlle Angrand; Alicia Quillévéré; Nadège Loaëc; Chrysoula Daskalogianni; Anton Granzhan; Marie-Paule Teulade-Fichou; Robin Fahraeus; Rodrigo Prado Martins; Marc Blondel
Journal:  Genes (Basel)       Date:  2019-08-31       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.